Tooluniverse Precision Medicine Stratification

This splits patients into treatment groups based on genomic, clinical, and pharmacogenomic data. It runs a nine-phase pipeline that routes through disease-specific logic (cancer gets TMB/MSI stratification, metabolic diseases get complication risk scoring, rare diseases get genotype-phenotype matching). It fetches from ClinVar, PharmGKB, cBioPortal, OpenTargets, and GWAS databases, then computes a 0-100 precision medicine risk score with evidence tiers for every finding. The workflow is compute-heavy: it expects you to run Python for actual statistical analysis rather than just describe what you'd do. Best for cases where you need a full stratification report with treatment recommendations, not just variant interpretation. The documentation is thorough with scoring matrices and worked examples across six disease types.

skills.sh installs: 377
GitHub stars: 1.8K
last updated: Aug 21, 2026

View on GitHub

Install

$ npx -y skills add mims-harvard/tooluniverse --skill tooluniverse-precision-medicine-stratification --agent claude-code

Installs into .claude/skills of the current project.

Files

Precision Medicine Patient Stratification

Transform patient genomic and clinical profiles into actionable risk stratification, treatment recommendations, and personalized therapeutic strategies.

Reasoning Before Searching

Stratification means splitting patients into groups that respond differently to a treatment or have different prognoses. Ask these questions before running any tools:

What molecular feature predicts response? Candidates: somatic mutation (e.g., EGFR L858R), germline variant (e.g., BRCA1 LoF), expression level (e.g., HER2 overexpression), germline pharmacogenomic variant (e.g., CYP2C19 PM), or composite biomarker (e.g., TMB-H + MSI-H).
Is the predictive feature actionable? Knowing it must change treatment — either the drug choice, dose, or monitoring plan. A variant with prognostic value but no therapeutic consequence is not a stratification biomarker.
What is the evidence level for the stratifier? FDA-approved companion diagnostic (T1) vs. exploratory (T4) changes how much weight to place on the finding.

SKILL.md on GitHub